Authors: Newhall-Perry, K Law, NJ Ramos, B Sterz, M Wong, WK Bulpitt, KJ Park, G Lee, M Clements, P Paulus, HE

Citation: K. Newhall-perry et al., Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis, J RHEUMATOL, 27(5), 2000, pp. 1156-1163

Authors: Paulus, HE Bulpitt, KJ Ramos, B Park, G Wong, WK

Citation: He. Paulus et al., Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis, ARTH RHEUM, 43(12), 2000, pp. 2743-2750

Authors: Weinblatt, ME Kremer, JM Bankhurst, AD Bulpitt, KJ Fleischmann, RM Fox, RI Jackson, CG Lange, M Burge, DJ

Citation: Me. Weinblatt et al., A trial of etanercept, a recombinant tumor necrosis factor receptor : Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N ENG J MED, 340(4), 1999, pp. 253-259

Authors: Moreland, LW Schiff, MH Baumgartner, SW Tindall, EA Fleischmann, RM Bulpitt, KJ Weaver, AL Keystone, EC Furst, DE Mease, PJ Ruderman, EM Horwitz, DA Arkfeld, DG Garrison, L Burge, DJ Blosch, CM Lange, MLM McDonnell, ND Weinblatt, ME

Citation: Lw. Moreland et al., Etanercept therapy in rheumatoid arthritis - A randomized, controlled trial, ANN INT MED, 130(6), 1999, pp. 478